Cargando…

P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

Detalles Bibliográficos
Autores principales:	Kuo, K. H. M., Layton, D. M., Lal, A., Al-Samkari, H., Bhatia, J., Kosinski, P. A., Tong, B., Lynch, M., Uhlig, K., Vichinsky, E. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428967/ http://dx.doi.org/10.1097/01.HS9.0000848944.56958.95

Ejemplares similares

S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K, et al.
Publicado: (2022)

P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K, et al.
Publicado: (2022)

P1546: ACTIVATE-KIDST: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
por: Grace, R. F., et al.
Publicado: (2022)

P1547: ACTIVATE-KIDS: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
por: Grace, R. F., et al.
Publicado: (2022)

P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
por: van Beers, Eduard, et al.
Publicado: (2023)

P1565: MITAPIVAT IMPROVES INEFFECTIVE ERYTHROPOIESIS AND REDUCES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
por: van Beers, E. J., et al.
Publicado: (2022)

P1545: DURABILITY OF HEMOGLOBIN RESPONSE AND REDUCTION IN TRANSFUSION BURDEN IS MAINTAINED OVER TIME IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT IN A LONG-TERM EXTENSION STUDY
por: Grace, R. F., et al.
Publicado: (2022)

Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias
por: Al-Samkari, Hanny, et al.
Publicado: (2021)

P1543: MITAPIVAT DECREASES THE NEED FOR TRANSFUSIONS SECONDARY TO POORLY TOLERATED ANEMIA AND ACUTE EVENTS COMPARED TO PLACEBO IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
por: Al-Samkari, H., et al.
Publicado: (2022)

Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice
por: Mattè, Alessandro, et al.
Publicado: (2023)

P1548: LONG-TERM TREATMENT WITH ORAL MITAPIVAT IS ASSOCIATED WITH NORMALIZATION OF HEMOGLOBIN LEVELS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
por: Barcellini, W., et al.
Publicado: (2022)

P1544: BONE MINERAL DENSITY REMAINS STABLE IN PYRUVATE KINASE DEFICIENCY PATIENTS RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT
por: Al-Samkari, H., et al.
Publicado: (2022)

The transfusion management of beta thalassemia in the United States
por: Lal, Ashutosh, et al.
Publicado: (2021)

P1477: MITAPIVAT EFFICACY IN ADULTS WITH PYRUVATE KINASE DEFICIENCY AND BASELINE HEMOGLOBIN LEVELS >10 G/DL
por: Grace, Rachael F., et al.
Publicado: (2023)

Right in time: Mitapivat for the treatment of anemia in α- and β-thalassemia
por: Musallam, Khaled M., et al.
Publicado: (2022)

Treating pyruvate kinase deficiency with Mitapivat: a short communication
por: Larik, Muhammad Omar, et al.
Publicado: (2023)

P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

P1735: IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN MITAPIVAT-TREATED PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A DESCRIPTIVE ANALYSIS FROM THE PHASE 3 ACTIVATE TRIAL
por: Kuo, K. H., et al.
Publicado: (2022)

Pituitary iron and factors predictive of fertility status in transfusion-dependent thalassemia
por: Singer, Sylvia T., et al.
Publicado: (2020)

The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry
por: Schwab, Marisa E., et al.
Publicado: (2022)

1522. Predictors of Weight Gain in People Living with HIV
por: Pedersen, Karen B H, et al.
Publicado: (2023)

Visceral Leishmaniasis during Italian Renaissance, 1522–1562
por: Nerlich, Andreas G., et al.
Publicado: (2012)

AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and adenosine triphosphate levels over a broad range of PKLR genotypes
por: Rab, Minke A.E., et al.
Publicado: (2020)

Laparoscopic Treatment of 1522 Adnexal Masses: An 8-Year Experience
por: Grammatikakis, I., et al.
Publicado: (2015)

P1703: ECONOMIC BURDEN OF TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN THE UNITED STATES
por: Udeze, C., et al.
Publicado: (2022)

Ocular abnormalities in multi-transfused beta-thalassemia patients
por: Jafari, Reza, et al.
Publicado: (2015)

Quality of life in transfusion-dependent thalassemia patients
por: Alzahrani, Rizqallah A., et al.
Publicado: (2017)

Mutational analysis of thalassemia in transfusion-dependent beta-thalassemia patients from central India
por: Shrivastava, Manisha, et al.
Publicado: (2019)

P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
por: van Dijk, Myrthe, et al.
Publicado: (2023)

Prevalence and specificities of red cell alloantibodies in transfusion-dependent beta thalassemia patients in Yazd
por: Vaziri, M, et al.
Publicado: (2015)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M.J., et al.
Publicado: (2023)

5588005 IMPACT OF COVID-19 PANDEMIC TO PRE-TRANSFUSION HEMOGLOBIN LEVEL AND FREQUENCY OF TRANSFUSION IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS IN INDONESIA
por: Dewi, M.K.D., et al.
Publicado: (2023)

β-Thalassemia Mutations among Transfusion-Dependent Thalassemia Major Patients in Northern Iraq
por: Al-Allawi, Nasir A. S., et al.
Publicado: (2010)

PSUN160 Transfusion Related Endocrinopathies and Thalassemia (TREAT) Study
por: Erkin-Cakmak, Ayca, et al.
Publicado: (2022)

Génesis histórica de Chiapas, 1522-1532 : el conflicto entre Portocarrero y Mazariegos /
por: Lenkersdorf, Gudrun
Publicado: (1993)

Heart involvement in transfusion-dependent beta-thalassemia with conventional echocardiography
por: Esfahani, Hossein, et al.
Publicado: (2021)

Alpha‐thalassemia. Case report alpha‐thalassemia in a Costa Rican family, A case report
por: Solano‐Vargas, Mariela, et al.
Publicado: (2020)

PB2247: PHARMACOKINETIC MODELING AND SIMULATION TO SUPPORT MITAPIVAT DOSE SELECTION USED IN PEDIATRIC PHASE III STUDIES
por: Yin, O., et al.
Publicado: (2022)

PB2339: PROJECTED LIFETIME ECONOMIC BURDEN OF TRANSFUSION DEPENDENT BETA-THALASSEMIA IN THE UNITED STATES
por: Udeze, C., et al.
Publicado: (2022)

P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M. J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9qg4e55j06dem71h1202lsjnee